Egetis Therapeutics Eligible for FDA Rare Pediatric Disease Priority Review Voucher
Egetis Therapeutics AB (STO:EGTX) stands to receive a Priority Review Voucher if one of its candidate therapies for rare pediatric diseases is approved under the U.S. Food and Drug Administration's Rare Pediatric Disease Priority Review Program, a scheme that has been extended through 2029. The voucher can expedite regulatory review of a future app…